Introduction {#sec1-2470547019838570}
============

Neurosteroids are naturally occurring molecules synthesized de novo in the brain from cholesterol.^[@bibr1-2470547019838570]^ Pregnenolone is synthesized from cholesterol and serves as a precursor for other neurosteroids, including the pregnane neurosteroids, such as allopregnanolone, pregnanolone, epiallopregnanolone, epipregnanolone, and tetrahydrodeoxycorticosterone (THDOC), as well as androstane neurosteroids, such as androsterone.^[@bibr2-2470547019838570]^ In addition to synthesis in the brain, steroids are also synthesized in the periphery, and these neurosteroids appear to cross the blood--brain barrier and mediate stress-signaling pathways.^[@bibr3-2470547019838570],[@bibr4-2470547019838570]^ Neurosteroids impact pathways that modulate gene expression and rapidly alter excitatory and inhibitory neurotransmission through ligand-gated ion channels, including gamma-aminobutyric acid (GABA) type A^[@bibr5-2470547019838570],[@bibr6-2470547019838570]^ and *N*-methyl-[D]{.smallcaps}-aspartate receptors,^[@bibr7-2470547019838570]^ as well as other cell surface receptors.^[@bibr8-2470547019838570]^ For example, allopregnanolone, pregnanolone, THDOC, and androsterone are positive allosteric modulators of GABA~A~ receptors, while epiallopregnanolone and epipregnanolone are negative allosteric modulators of GABA~A~ receptors.^[@bibr9-2470547019838570],[@bibr10-2470547019838570]^ In addition, neurosteroids affect multiple cellular processes, such as myelination, apoptosis, neuritic outgrowth, and neurogenesis,^[@bibr4-2470547019838570],[@bibr6-2470547019838570],[@bibr8-2470547019838570]^ as well as neuronal systems, including those underlying cognition, emotion, and motivation.^[@bibr11-2470547019838570]^

Neurosteroids have been implicated in stress response regulation^[@bibr6-2470547019838570]^ and the pathophysiology underlying several mental disorders, especially stress and stress-related psychiatric disorders.^[@bibr12-2470547019838570][@bibr13-2470547019838570][@bibr14-2470547019838570][@bibr15-2470547019838570][@bibr16-2470547019838570]--[@bibr17-2470547019838570]^ Multiple studies have shown that the endogenous production of neurosteroids is affected by stress^[@bibr16-2470547019838570]^ and that patients with various neuropsychiatric conditions, including bipolar disorder, schizophrenia, major depression, traumatic brain injury, and post-traumatic stress disorder (PTSD), exhibit disruptions of their hypothalamic-pituitary-adrenocortical axis and altered levels, as well as reactivity, of neurosteroids in peripheral blood, cerebrospinal fluid, and postmortem brain tissue.^[@bibr2-2470547019838570],[@bibr8-2470547019838570],[@bibr12-2470547019838570],[@bibr18-2470547019838570]^ Both clinical and preclinical studies have shown that the levels of neurosteroids, particularly those that impact GABAergic neurotransmission, are decreased in subjects with PTSD^[@bibr2-2470547019838570],[@bibr19-2470547019838570]^ and differ by sex.^[@bibr2-2470547019838570],[@bibr19-2470547019838570]^

A number of animal models have shown that neurosteroids are involved in the development and treatment of PTSD-related behaviors.^[@bibr2-2470547019838570],[@bibr20-2470547019838570]^ The administration of an allopregnanolone stimulant alleviates fear extinction deficits in a rodent model of PTSD that exhibits decreased allopregnanolone levels in corticolimbic regions.^[@bibr21-2470547019838570],[@bibr22-2470547019838570]^ The biosynthesis of allopregnanolone is also decreased in patients with PTSD.^[@bibr15-2470547019838570],[@bibr23-2470547019838570]^ In addition, androsterone, an inhibitory androstane neurosteroid, and its precursor, dehydroepiandrosterone, have been shown to be neuroprotective and associated with stress resilience.^[@bibr15-2470547019838570],[@bibr24-2470547019838570]^ Both the serum and brain levels of androsterone increase in response to acute stress.^[@bibr25-2470547019838570]^

Accumulating evidence collected from postmortem and neuroimaging studies of PTSD suggests that brain structure and function, especially in subregions of frontal cortex, amygdala, and hippocampus, are altered in patients with PTSD.^[@bibr26-2470547019838570],[@bibr27-2470547019838570]^ The hippocampal and anterior cingulate cortical volumes are decreased in patients with PTSD.^[@bibr28-2470547019838570]^ Functional imaging studies of patients with PTSD have reported hypoactivity of the ventromedial prefrontal cortex, including the medial orbital frontal cortex (mOFC).^[@bibr29-2470547019838570][@bibr30-2470547019838570][@bibr31-2470547019838570][@bibr32-2470547019838570]--[@bibr33-2470547019838570]^ Few postmortem studies of subjects with PTSD have examined the mOFC. Interestingly, studies involving human postmortem mOFC have reported stress-induced differences in dendritic spine density^[@bibr34-2470547019838570]^ and reductions in spine density in subjects with PTSD.^[@bibr35-2470547019838570]^ The mOFC is involved in the extinction of conditioned fear and reward processing,^[@bibr36-2470547019838570],[@bibr37-2470547019838570]^ processes that are abnormal in subjects with PTSD.^[@bibr38-2470547019838570],[@bibr39-2470547019838570]^ Therefore, in this study, neurosteroid levels were quantified in the mOFC of postmortem subjects with PTSD in order to gain a greater understanding of how the mOFC may contribute to dysregulation of these pathways.

The pathophysiological processes underlying the observed alterations of neurosteroid levels in patients with PTSD remain unclear. In addition, to our knowledge, no studies to date have measured neurosteroid levels in postmortem brain tissue from individuals with PTSD. Therefore, guided by prior research, the aim of this preliminary study was to compare neurosteroid levels in the mOFC of postmortem subjects with PTSD and controls.

Methods {#sec2-2470547019838570}
=======

Fresh-frozen tissue was obtained from the brains of subjects with PTSD (*n* = 18) and controls (*n* = 35) from the Duke Neuropsychiatric Brain Bank. Informed consent for brain donation was obtained from the next of kin (NOK) of each subject. All aspects of this work were approved by the Duke University School of Medicine institutional review board.

Information about the donor's medical history was obtained from interviews with the NOK that also included a structured interview using the Mini-International Neuropsychiatric Interview.^[@bibr40-2470547019838570]^ Psychiatric diagnoses were determined by a consensus review process conducted by at least two psychiatrists who reviewed the NOK interviews and medical records of each donor. In any cases involving disagreement, a third psychiatrist was consulted to determine the diagnosis. The criteria in the *Diagnostic and Statistical Manual of Mental Disorders*, Version IV,^[@bibr41-2470547019838570]^ were utilized for determining postmortem psychiatric diagnosis. Subjects were categorized as controls if their medical records and NOK interviews confirmed they had no known history of psychiatric symptoms or substance abuse.

Subject Demographics {#sec3-2470547019838570}
--------------------

A total of 53 subjects were included in this study (PTSD: *n* = 18, controls: *n* = 35; see [Table 1](#table1-2470547019838570){ref-type="table"}). The groups did not differ significantly for age or sex. However, the groups differed significantly for postmortem interval (PMI; *t*~51~ = 2.57; *p* = 0.013), ethnicity (Fisher's exact test, *p* = 0.001), and smoking (Fisher's exact test, *p* = 0.001). Compared to the control group, the subjects with PTSD had a shorter PMI (26.6 ± 10 h vs. 35.5 ± 12.8 h), a greater racial proportion more likely to be white (72.2% vs. 28.6%), and a history of smoking (94.4% vs. 20.0%) (see [Table 1](#table1-2470547019838570){ref-type="table"}). Table 1.Subject demographic information.PTSD *n* = 18Control *n* = 35*p* valueSex (% male)66.7%54.3%NSAge (years)42.4 ± 13.945.9 ± 13.4NSPMI (hours)26.6 ± 10.035.5 ± 12.80.013Ethnicity (% white)72.2%28.6%≤0.001^[a](#table-fn2-2470547019838570){ref-type="table-fn"}^Comorbid MDD (%)50%0%≤0.001^[a](#table-fn2-2470547019838570){ref-type="table-fn"}^Smoking (% yes)94.4%20.0%≤0.001^[a](#table-fn2-2470547019838570){ref-type="table-fn"}^[^2][^3]

Postmortem Brain Samples {#sec4-2470547019838570}
------------------------

All specimens were free of confounding gross or microscopic neuropathology. Fresh-frozen tissue samples from the mOFC (Brodmann area 11) were sampled from each subject, and approximately 80 mg of tissue was collected from cryosections. The collected tissue from each sample was stored in individually washed and salinized vials at −80℃ until analysis.

Quantification of Neurosteroids {#sec5-2470547019838570}
-------------------------------

The levels of neurosteroids, including pregnenolone, allopregnanolone, pregnanolone, epiallopregnanolone, epipregnanolone, THDOC, and androsterone were determined in each subject using gas chromatography-tandem mass spectrometry (GC/MS/MS), preceded by high-performance liquid chromatography (HPLC). This technique has a limit of quantification of 2 pg, as described previously,^[@bibr17-2470547019838570],[@bibr42-2470547019838570],[@bibr43-2470547019838570]^ and was modified to use electron impact ionization mode.

The tissue was initially subjected to triplicate liquid-liquid extractions using ethyl acetate. Combined extracts were further purified by collecting the fractions of interest from an Agilent 1100 HPLC system equipped with a 25 cm × 4.6 mm × 5 µm LiChrosorb® Diol-5 HPLC column under normal-phase conditions. Purified samples were subsequently derivatized with heptafluoroacetic anhydride and injected onto an Agilent 7013A gas chromatography/triple quadrupole mass spectrometer (GC/MS/MS) with chromatographic separations performed on the interfaced Agilent 7890B GC. A 2 -µl splitless injection was used on a 30.0 m × 0.25 mm × 0.25 µm installed HP-5MS GC column.

Twenty percent of the injections were performed in duplicate. The mean intra-assay coefficients of variation for the subset of samples (20% of the entire sample set) run in duplicate were 4.8% for pregnenolone, 2.6% for allopregnanolone, 12.1% for pregnanolone, 4.7% for epiallopregnanolone, 7.9% for epipregnanolone, 7.2% for THDOC, and 6.5% for androsterone. Multiple reactions monitoring transition states were optimized for precursor and product ions using the two most intense precursor-to-product ion transitions for each analyte. The more intense transition was used for target ion quantitation, and the second one was used as the reference ion for structural confirmation (qualifier ion) and added specificity. All neurosteroid measurements were conducted blind to group condition.

Statistical Analysis {#sec6-2470547019838570}
--------------------

The descriptive data are presented as means, standard deviations, minimums, lower quartiles (Q1), medians, upper quartiles (Q3), and maximums separately for males and females. Differences in the levels of neurosteroids between the subjects with PTSD and controls were assessed in R (version 3.4.4, 2018-03-15).^[@bibr44-2470547019838570]^ The initial analyses stratified the data by gender and compared the two groups using Wilcoxon rank-sum tests. Subsequently, linear regression analyses controlling for smoking status, PMI, and age, which have been shown to affect postmortem and/or neurosteroid measures,^[@bibr17-2470547019838570],[@bibr45-2470547019838570],[@bibr46-2470547019838570]^ were used to examine the data for each neurosteroid in all of the subjects. Because neurosteroid levels (and possibly also the underlying pathophysiology of PTSD) differ according to gender,^[@bibr46-2470547019838570],[@bibr47-2470547019838570]^ between-group differences were next examined within each gender using the estimated marginal means that were derived from the regression. Prior to the linear regression analyses, the data for each neurosteroid were transformed to normality using a Box--Cox transformation^[@bibr48-2470547019838570]^ via the following formula: *T*(*Y*) = (*Y^λ^* − 1)/*λ*, where *Y* is the neurosteroid level, and *λ* is the transformation parameter. For *λ* = 0, the formula ln (*Y* + 1) was used in place of the above formula. *λ* values that ranged from −2 to 2 with 0.1 increments were used to transform each neurosteroid level, and the appropriate *λ* was selected based on the highest Shapiro--Wilk test statistic and the significance value closest to 1.0 (indicating that the transformed values were normally distributed). *p* values \< 0.05 were considered statistically significant, and *p* values \> 0.05 and \< 0.10 were reported as trends. Effect sizes for significant comparisons were calculated based on *p* values and number of subjects.^[@bibr49-2470547019838570]^

Results {#sec7-2470547019838570}
=======

Neurosteroid Levels in the mOFC {#sec8-2470547019838570}
-------------------------------

The neurosteroids pregnenolone, allopregnanolone, pregnanolone, epiallopregnanolone, epipregnanolone, THDOC, and androsterone were all detected at physiologically relevant concentrations in the mOFC of the subjects with PTSD and controls (see [Table 2](#table2-2470547019838570){ref-type="table"} and [Figure 1](#fig1-2470547019838570){ref-type="fig"}).^[@bibr42-2470547019838570]^ Figure 1.Box and dot plots of the neurosteroid concentrations in units of (pg/g) (a. pregnenolone, b. allopregnanolone, c. pregnanolone, d. epiallopregnanolone, e. epipregnanolone, f. THDOC, g. androsterone) stratified by sex and group. Yellow indicates control subjects, and blue indicates subjects with post-traumatic stress disorder. The lines indicate median values, while the lower and upper box boundaries indicate first and third quartiles, respectively. The red lines indicate group mean values. \**p* \< 0.05.THDOC: tetrahydrodeoxycorticosterone. Table 2.Neurosteroid concentrations (pg/g) in the medial orbitofrontal cortex.*N*MeanSDMinQ1MedianQ3MaxPregnenolone5315,752.226,502.4912.43,751.97,026.414,521.9146,702.8Allopregnanolone53262.7473.237.291.8112.6223.23,152.3Pregnanolone5326.144.90.08.213.429.0320.6Epiallopregnanolone53213.9226.916.892.2121.2188.61,044.9Epipregnanolone5328.925.40.012.820.637.7145.2THDOC5383.6251.30.012.028.383.71,831.6Androsterone53244.0228.170.7141.4185.6267.71,515.7[^4]

Group Differences in Neurosteroids Stratified by Sex {#sec9-2470547019838570}
----------------------------------------------------

### Primary Analysis {#sec10-2470547019838570}

In the primary analysis (see [Tables 3](#table3-2470547019838570){ref-type="table"} and [4](#table4-2470547019838570){ref-type="table"}, [Figure 1](#fig1-2470547019838570){ref-type="fig"}), the raw data for each neurosteroid were stratified by gender and compared between the two groups. The results revealed that, compared to the control subjects, males with PTSD had significantly decreased levels of allopregnanolone (*p* = 0.03, effect size = 0.8307) and a trend for decreased levels of androsterone (*p* = 0.08, effect size = 0.6666; [Table 3](#table3-2470547019838570){ref-type="table"}). Females with PTSD had significantly increased levels of pregnenolone (*p* = 0.03, effect size = 1.0964) and a trend for increased levels of pregnanolone (*p* = 0.07, effect size = 0.9129; [Table 4](#table4-2470547019838570){ref-type="table"}). Table 3.Unadjusted neurosteroid concentrations (pg/g) in the medial orbitofrontal cortex among males.*N*MeanSDMinQ1MedianQ3Max*p* value^[a](#table-fn5-2470547019838570){ref-type="table-fn"}^Pregnenolone Control1914,824.027,356.3912.43,650.36,678.09,305.8114,766.7 PTSD1215,246.318,440.32,520.22,957.88,714.417,235.666,197.5 Overall3114,987.423,953.0912.43,271.77,026.413,777.4114,766.70.516Allopregnanolone Control19208.1280.272.099.0105.5166.61,302.3 PTSD12125.2120.037.663.890.2113.4479.9 Overall31176.0232.637.690.9101.4161.81,302.3**0.032** [\*](#table-fn6-2470547019838570){ref-type="table-fn"}Pregnanolone Control1919.316.11.910.112.627.169.8 PTSD1214.311.40.05.112.718.639.7 Overall3117.414.50.07.812.623.069.80.465Epiallopregnanolone Control19175.8152.579.892.9108.5171.2624.9 PTSD12133.0121.937.471.6107.8128.0496.7 Overall31159.3140.937.491.8108.5165.2624.90.44Epipregnanolone Control1935.932.85.512.030.948.2145.2 PTSD1220.911.97.312.319.226.546.2 Overall3130.127.45.512.023.040.2145.20.23THDOC Control1943.150.52.98.820.853.8195.3 PTSD1241.851.20.010.722.748.3173.7 Overall3142.649.90.08.820.850.7195.30.84Androsterone Control19258.6183.5100.4156.1203.5290.3930.5 PTSD12189.4106.970.7140.2158.5202.8472.0 Overall31231.8159.970.7149.9191.5259.2930.50.081[^5][^6][^7] Table 4.Unadjusted neurosteroid levels (pg/g) in the medial orbitofrontal cortex among females.*N*MeanSDMinQ1MedianQ3Max*p* value^[a](#table-fn8-2470547019838570){ref-type="table-fn"}^Pregnenolone Control169,189.18,933.31,702.63,636.66,651.810,077.933,828.7 PTSD637,205.454,121.16,543.510,307.817,739.224,442.4146,702.8 Overall2216,829.930,290.31,702.64,698.87,301.015,273.4146,702.8**0.033** [\*](#table-fn9-2470547019838570){ref-type="table-fn"}Allopregnanolone Control16391.3776.655.389.2120.7237.83,152.3 PTSD6368.1286.137.2152.2328.5611.2715.6 Overall22385.067.137.294.1163.8263.13,152.30.376Pregnanolone Control1620.919.90.08.614.523.071.3 PTSD685.2117.36.729.145.163.9320.6 Overall2238.466.50.09.320.032.1320.60.071Epiallopregnanolone Control16222.6237.854.7106.1145.9287.91,044.9 PTSD6472.5384.216.8199.6427.9735.41,001.0 Overall22290.8297.516.8112.5164.6317.21,044.90.160Epipregnanolone Control1625.120.75.214.517.729.393.3 PTSD632.729.20.014.527.144.481.3 Overall2227.122.80.014.117.835.093.30.560THDOC Control16163.8449.48.614.723.489.71,831.6 PTSD681.768.90.035.768.1128.9180.2 Overall22141.4383.10.015.329.392.11,831.60.420Androsterone Control16259.0346.180.5129.9149.2210.01,515.7 PTSD6267.5161.982.7156.1238.6371.5500.6 Overall22261.3303.180.5130.1161.2260.91,515.70.417[^8][^9][^10]

### Linear Regression Models Adjusting for Potential Confounds {#sec11-2470547019838570}

We further analyzed the data for each neurosteroid by first transforming the data to normality using a Box--Cox transformation and then using a linear regression model that controlled for age, PMI, and smoking status. Between-group differences were then examined within each gender using the estimated marginal means derived from the regression. As shown in [Figure 2](#fig2-2470547019838570){ref-type="fig"} (Box--Cox transformed data with adjusted *p* values shown), compared to the control subjects, males with PTSD exhibited significantly decreased levels of androsterone (*t*~46~ = 2.37, *p* = 0.02, effect size = 0.6788) and a trend for decreased levels of allopregnanolone (*t*~46~ = 1.82, *p* = 0.08, effect size = 0.8932), while females with PTSD only had significantly increased levels of pregnanolone (*t*~46~ = −2.25, *p* = 0.03, effect size = 1.1215). Figure 2.Box and dot plots of the neurosteroid concentrations in units of (pg/g)λ (a. pregnenolone, b. allopregnanolone, c. pregnanolone, d. epiallopregnanolone, e. epipregnanolone, f. THDOC, g. androsterone) stratified by gender and group after Box--Cox transformation and controlling for age, postmortem interval, and smoking status. Yellow indicates control subjects, and blue indicates subjects with post-traumatic stress disorder. The lines indicate median values, while the lower and upper box boundaries indicate first and third quartiles, respectively. The red lines indicate group mean values. \**p* \< 0.05.THDOC: tetrahydrodeoxycorticosterone.

Discussion {#sec12-2470547019838570}
==========

To our knowledge, this study is the first to quantify neurosteroids in postmortem brain tissue of subjects with PTSD. The results of this preliminary study in the mOFC showed that the levels of androsterone (and to a lesser extent allopregnanolone) were decreased in males with PTSD compared with control males. Conversely, levels of pregnanolone were significantly increased in females with PTSD compared with control females. These results suggest that the levels of some neurosteroids may be altered in the mOFC of subjects with PTSD and that these alterations may differ by sex.

Previous reports have suggested that neurosteroids are decreased in subjects with PTSD.^[@bibr16-2470547019838570],[@bibr19-2470547019838570],[@bibr23-2470547019838570]^ For example, we previously reported that the serum levels of pregnenolone, allopregnanolone, and androsterone were significantly decreased in male patients with PTSD.^[@bibr50-2470547019838570]^ Similarly, a recent study has shown that the levels of allopregnanolone and pregnanolone in cerebrospinal fluid are negatively correlated with total PTSD symptoms in males with PTSD.^[@bibr19-2470547019838570]^ The present results in human postmortem brain tissue showing a significant reduction of androsterone and allopregnanolone in males with PTSD are consistent with these prior observations in peripheral samples. Although preliminary, the present results potentially converge to suggest a dysregulation of androsterone in males with PTSD in at least one brain region previously linked with PTSD. It is unclear why we found a significant increase in the levels of pregnanolone in females with PTSD. However, multiple studies have suggested that steroid levels exhibit sex differences^[@bibr51-2470547019838570]^ and that the pathophysiological mechanisms underlying PTSD in females may differ from those in males.^[@bibr52-2470547019838570]^ Additionally, as discussed in the limitations below, there are numerous potential confounds that impact the interpretations of male versus female findings in PTSD.

A number of neurosteroids, including allopregnanolone, pregnanolone, and androsterone act as positive allosteric modulators of the GABA~A~ receptor.^[@bibr6-2470547019838570]^ Changes in this receptor and its modulators are thought to reflect the pathophysiological mechanisms that underlie the anxiety observed in patients with PTSD.^[@bibr13-2470547019838570]^ The results of multiple studies have suggested that the levels of neurosteroids, including allopregnanolone, decrease in response to chronic stress.^[@bibr21-2470547019838570]^ Thus, our observed changes in the levels of neurosteroids in subjects with PTSD may reflect evidence that subjects with PTSD have impaired GABAergic neurotransmission, as reviewed elsewhere.^[@bibr6-2470547019838570],[@bibr15-2470547019838570],[@bibr16-2470547019838570]^

This preliminary study had a number of limitations. First, there was no information regarding menstrual status or whether subjects were taking supplemental hormones, all of which may have an effect on neurosteroid levels. For example, neurosteroid levels differ according to a female's menstrual, menopausal, and oral contraceptive use status,^[@bibr2-2470547019838570],[@bibr17-2470547019838570],[@bibr23-2470547019838570]^ which might have uniquely impacted the female PTSD group.^[@bibr27-2470547019838570]^ In addition, selective serotonin reuptake inhibitors, which are used to treat patients with PTSD, have been shown to induce allopregnanolone synthesis.^[@bibr53-2470547019838570],[@bibr54-2470547019838570]^ Second, the females with PTSD were slightly younger (age range: 35--51 years) than the female controls (age range: 44--57 years). Such an age difference could contribute to our finding of significantly higher levels of pregnanolone in the female subjects with PTSD since neurosteroids have been shown to decrease with age.^[@bibr55-2470547019838570]^ Third, smoking status differed significantly between the groups. In the control group, 20% of the subjects smoked, while 94.4% of the subjects with PTSD smoked. Subjects with PTSD have a higher incidence of smoking compared with that of the general population,^[@bibr56-2470547019838570]^ and smoking status needs to be accounted for in studies of PTSD.^[@bibr15-2470547019838570]^ However, previous findings that smoking is positively associated with allopregnanolone levels^[@bibr57-2470547019838570]^ suggest that our findings of decreased levels of allopregnanolone in male subjects with PTSD were not due to smoking and might actually underestimate the true levels in these subjects.

Because of these limitations and the relatively small number of samples included, the current results should be viewed as preliminary as they await replication in a larger sample of subjects carefully matched for age, smoking status, and PMI. Furthermore, neurosteroid levels should be measured in other brain regions, such as the prefrontal cortex, amygdala, and hippocampus, regions that have been directly implicated in the pathophysiology of PTSD.^[@bibr27-2470547019838570]^

Future directions include expanding the number of samples in these cohorts and examining neurosteroid expression levels in subjects with other diagnoses, such as major depression, as well as measuring the activity of enzymes involved in the production of neurosteroids, in order to gain better insight into the sex differences of neurosteroid levels in subjects with PTSD.

Conclusion {#sec13-2470547019838570}
==========

Consistent with prior and emerging literature, these preliminary results suggest that males with PTSD exhibit differences in the levels of some neurosteroids, particularly androsterone and allopregnanolone, in the mOFC. More extensive investigations of neurosteroids in larger samples and additional brain regions are needed.
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